Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies
Study objective: This systematic review and meta-analysis aimed to assess the efficacy and safety profile of treatment with inclisiran, a drug that has been recently approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Design: A systematic literat...
Main Authors: | Arrigo F.G. Cicero, Federica Fogacci, Alberto Zambon, Peter P. Toth, Claudio Borghi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | American Heart Journal Plus |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602222000441 |
Similar Items
-
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
by: Niki Katsiki, et al.
Published: (2023-04-01) -
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
by: Toshiyuki Nishikido
Published: (2023-01-01) -
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
by: Michael J. Wilkinson, et al.
Published: (2024-03-01) -
Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases
by: Victoria A. Korneva, et al.
Published: (2021-09-01) -
Familial Hypercholesterolemia
by: FENG Siqin, et al.
Published: (2023-01-01)